Skip to main content
MedPathMedPath Home
Clinical Trials/EUCTR2018-004888-31-FR
EUCTR2018-004888-31-FR
Active, not recruiting
Phase 1

ong-Term Follow-Up (LTFU) of Participants Treated with GSK Adoptive Cell Therapies - Adoptive cell therapy LTFU study

GlaxoSmithKline Research & Development Ltd0 sites171 target enrollmentJune 25, 2021
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsSynovial sarcoma, Non-small cell lung cancer (NSCLC), Myxoid/round cell liposarcoma (MRCLS), Multiple Myeloma & other indicationsMedDRA version: 20.0Level: PTClassification code 10042863Term: Synovial sarcomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.0Level: LLTClassification code 10028228Term: Multiple myelomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1Level: PTClassification code 10061873Term: Non-small cell lung cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: PTClassification code 10073137Term: Myxoid liposarcomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Therapeutic area: Diseases [C] - Cancer [C04]

Overview

Phase
Phase 1
Intervention
Not specified
Conditions
Synovial sarcoma, Non-small cell lung cancer (NSCLC), Myxoid/round cell liposarcoma (MRCLS), Multiple Myeloma & other indications
Sponsor
GlaxoSmithKline Research & Development Ltd
Enrollment
171
Status
Active, not recruiting
Last Updated
4 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
June 25, 2021
End Date
TBD
Last Updated
4 years ago
Study Type
Interventional clinical trial of medicinal product
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • •Type of Participant and Disease Characteristics
  • •1\. Participants who:
  • •a. Have received at least one infusion of a GSK adoptive cell therapy agent and
  • •b. Have completed a GSK sponsored or supported interventional study or have withdrawn from it, as defined by the interventional protocol or
  • •c. have completed treatment as part of managed access to a GSK adoptive cell therapy
  • •Participants who complete an interventional study will complete the assessments outlined in the interventional protocol prior to starting on this study.
  • •2\. Male or Female participants. Contraceptive use by men or women should be
  • •consistent with local regulations regarding the methods of contraception for those
  • •participating in clinical studies.
  • •a. Male Participants:

Exclusion Criteria

  • •Not applicable

Outcomes

Primary Outcomes

Not specified

Similar Trials

Active, not recruiting
Phase 1
ong-Term Follow-Up (LTFU) of Participants Treated with Adoptive Cell Therapieson-small cell lung cancer (NSCLC), Multiple Myeloma & other indications, Synovial sarcoma, Myxoid/round cell liposarcoma (MRCLS)MedDRA version: 21.1Level: PTClassification code: 10061873Term: Non-small cell lung cancer Class: 100000004864MedDRA version: 20.0Level: PTClassification code: 10073137Term: Myxoid liposarcoma Class: 100000004864MedDRA version: 21.0Level: LLTClassification code: 10028228Term: Multiple myeloma Class: 10029104MedDRA version: 20.0Level: PTClassification code: 10042863Term: Synovial sarcoma Class: 100000004864Therapeutic area: Diseases [C] - Neoplasms [C04]
CTIS2024-513033-21-00Adaptimmune LLC76
Active, not recruiting
Phase 1
Adoptive cell therapy LTFU studySynovial sarcomaMultiple myelomaNon-small cell lung cancerMyxoid liposarcomaMedDRA version: 20.0Level: PTClassification code 10042863Term: Synovial sarcomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1Level: PTClassification code 10061873Term: Non-small cell lung cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.0Level: LLTClassification code 10028228Term: Multiple myelomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: PTClassification code 10073137Term: Myxoid liposarcomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Therapeutic area: Diseases [C] - Cancer [C04]
EUCTR2018-004888-31-NLGlaxoSmithKline research & development Ltd.171
Active, not recruiting
Phase 1
Adoptive cell therapy LTFU studySynovial sarcoma, Non-small cell lung cancer (NSCLC), Myxoid/round cell liposarcoma (MRCLS), Multiple Myeloma & other indicationsMedDRA version: 20.0Level: PTClassification code 10042863Term: Synovial sarcomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.0Level: LLTClassification code 10028228Term: Multiple myelomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1Level: PTClassification code 10061873Term: Non-small cell lung cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: PTClassification code 10073137Term: Myxoid liposarcomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Therapeutic area: Diseases [C] - Cancer [C04]
EUCTR2018-004888-31-SEAdaptimmune LLC171
Not yet recruiting
Phase 2
ong-Term Follow-Up (LTFU) of Participants Treated with Adoptive Cell Therapies (study 208750)cancertumors10027655
NL-OMON52738Adaptimmune LLC1
Active, not recruiting
Phase 1
ong term follow-up clinical trial to the MUST trial which investigates which treatment of systemic steroid treatment and a steroid implant which is inserted into the eye gives the best visual outcome for patients with chronic eye inflammation.
EUCTR2011-001078-25-GBational Institute of Health, National Eye Institute250